File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma

Titleα-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma
Authors
Issue Date1989
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1989, v. 9 n. 1, p. 110-115 How to Cite?
AbstractTwo hundred ninety patients (203 men, 87 women), age 7 to 74 years (mean: 39.1 years), with chronic hepatitis B virus infection, were prospectively followed for a period of 1 to 4 years to determine the value of α-fetoprotein monitoring in the early detection of hepatocellular carcinoma. At presentation, 66% of the patients were asymptomatic, 19% had chronic hepatitis and 15% had established cirrhosis. Forty-four (15%) patients had elevated α-fetoprotein levels on one or more occasions during the study period. Twenty patients with normal α-fetoprotein levels at presentation developed elevated α-fetoprotein levels during the course of follow-up, whereas 24 patients had elevated α-fetoprotein levels at presentation. Six (14%) of these 44 patients (five men and one woman), age 23 to 66 years, had persistent or progressive increase in α-fetoprotein levels and were confirmed to have hepatocellular carcinoma. In four patients, the α-fetoprotein levels were below 500 ng per ml at the time of tumor localization. Only three patients had resectable tumors. All six patients would have been missed if α-fetoprotein screening was restricted to men above the age of 40 with cirrhosis and anti-HBe. Of the remaining 38 patients, elevation in α-fetoprotein levels in 18 patients was associated with exacerbations of the underlying liver disease and/or significant changes in level of hepatitis B virus replication, but in 20 patients, no apparent cause could be identified. The elevation in AFP levels exceeded 200 ng per ml in 26% and persisted beyond 6 months in 15% of these patients. We observed that elevation in α-fetoprotein levels occurred quite frequently in patients with chronic hepatitis B virus infection. The differentiation between benign and malignant causes of α-fetoprotein elevation was at times difficult. Thus, α-fetoprotein monitoring alone is not a satisfactory tool in the early diagnosis of hepatocellular carcinoma.
Persistent Identifierhttp://hdl.handle.net/10722/161795
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:15:05Z-
dc.date.available2012-09-05T05:15:05Z-
dc.date.issued1989en_US
dc.identifier.citationHepatology, 1989, v. 9 n. 1, p. 110-115en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/161795-
dc.description.abstractTwo hundred ninety patients (203 men, 87 women), age 7 to 74 years (mean: 39.1 years), with chronic hepatitis B virus infection, were prospectively followed for a period of 1 to 4 years to determine the value of α-fetoprotein monitoring in the early detection of hepatocellular carcinoma. At presentation, 66% of the patients were asymptomatic, 19% had chronic hepatitis and 15% had established cirrhosis. Forty-four (15%) patients had elevated α-fetoprotein levels on one or more occasions during the study period. Twenty patients with normal α-fetoprotein levels at presentation developed elevated α-fetoprotein levels during the course of follow-up, whereas 24 patients had elevated α-fetoprotein levels at presentation. Six (14%) of these 44 patients (five men and one woman), age 23 to 66 years, had persistent or progressive increase in α-fetoprotein levels and were confirmed to have hepatocellular carcinoma. In four patients, the α-fetoprotein levels were below 500 ng per ml at the time of tumor localization. Only three patients had resectable tumors. All six patients would have been missed if α-fetoprotein screening was restricted to men above the age of 40 with cirrhosis and anti-HBe. Of the remaining 38 patients, elevation in α-fetoprotein levels in 18 patients was associated with exacerbations of the underlying liver disease and/or significant changes in level of hepatitis B virus replication, but in 20 patients, no apparent cause could be identified. The elevation in AFP levels exceeded 200 ng per ml in 26% and persisted beyond 6 months in 15% of these patients. We observed that elevation in α-fetoprotein levels occurred quite frequently in patients with chronic hepatitis B virus infection. The differentiation between benign and malignant causes of α-fetoprotein elevation was at times difficult. Thus, α-fetoprotein monitoring alone is not a satisfactory tool in the early diagnosis of hepatocellular carcinoma.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.subject.meshAge Factorsen_US
dc.subject.meshCarcinoma, Hepatocellular - Diagnosisen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshHepatitis B - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms - Diagnosisen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTaiwanen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshAlpha-Fetoproteins - Analysisen_US
dc.titleα-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hep.1840090119-
dc.identifier.pmid2461890-
dc.identifier.scopuseid_2-s2.0-0024541162en_US
dc.identifier.volume9en_US
dc.identifier.issue1en_US
dc.identifier.spage110en_US
dc.identifier.epage115en_US
dc.identifier.isiWOS:A1989R509900018-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats